MiMedx Group's (MDXG) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald reaffirmed its “overweight” rating on MiMedx Group and maintained an $8.00 price target, implying approximately 87% upside from the prior close.
• Analyst sentiment remains mixed but leans positive: six analysts rate the stock a Buy and one rates it a Sell, resulting in a “Moderate Buy” consensus and an average price target of $8.50.
• MiMedx reported quarterly revenue of $64.36 million, ahead of the $63.46 million consensus estimate, while matching expectations with a loss of $0.05 per share. Institutional investors own approximately 79.15% of the company.

MiMedx Group (NASDAQ:MDXG - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. Cantor Fitzgerald's target price would suggest a potential upside of 87.35% from the company's previous close.

Several other equities research analysts have also recently commented on the company. Weiss Ratings reissued a "sell (d)" rating on shares of MiMedx Group in a research note on Thursday. Citizens Jmp lowered their price objective on MiMedx Group from $7.00 to $6.00 and set a "market outperform" rating for the company in a research report on Thursday, April 30th. Finally, Wall Street Zen downgraded shares of MiMedx Group from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, MiMedx Group has an average rating of "Moderate Buy" and a consensus target price of $8.50.

MiMedx Group Stock Performance

MiMedx Group stock opened at $4.27 on Monday. The stock has a 50-day simple moving average of $4.04 and a 200 day simple moving average of $4.14. The stock has a market capitalization of $622.40 million, a price-to-earnings ratio of 106.78 and a beta of 1.45. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The company had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. On average, research analysts anticipate that MiMedx Group will post -0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. Kemnay Advisory Services Inc. acquired a new stake in MiMedx Group during the 4th quarter worth $48,000. Sunbelt Securities Inc. acquired a new position in shares of MiMedx Group in the 1st quarter valued at approximately $42,000. Jain Global LLC acquired a new stake in MiMedx Group during the 4th quarter worth approximately $73,000. E Fund Management Co. Ltd. bought a new position in MiMedx Group in the second quarter valued at approximately $45,000. Finally, Virtu Financial LLC acquired a new position in shares of MiMedx Group in the fourth quarter valued at approximately $78,000. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source